<DOC>
	<DOCNO>NCT02479022</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) insulin 320 healthy subject .</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Pharmacokinetics Pharmacodynamics Insulin 320 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male , age 1855 year ( inclusive ) time sign informed consent Body mass index 18.528.0 kg/m^2 ( inclusive ) Subject consider healthy base medical history , physical examination , result vital sign , electrocardiograms clinical laboratory test perform screen visit , judge investigator Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define sign informed consent Any disorder , opinion investigator , might jeopardise subject 's safety compliance protocol Presence clinically significant acute chronic gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>